CA2158425C - Diagnostic et traitement pour les dysfonctions erectiles - Google Patents

Diagnostic et traitement pour les dysfonctions erectiles Download PDF

Info

Publication number
CA2158425C
CA2158425C CA002158425A CA2158425A CA2158425C CA 2158425 C CA2158425 C CA 2158425C CA 002158425 A CA002158425 A CA 002158425A CA 2158425 A CA2158425 A CA 2158425A CA 2158425 C CA2158425 C CA 2158425C
Authority
CA
Canada
Prior art keywords
erection
peptide
arg
group
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002158425A
Other languages
English (en)
Other versions
CA2158425A1 (fr
Inventor
Mac E. Hadley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Competitive Technologies Inc
Original Assignee
Competitive Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Competitive Technologies Inc filed Critical Competitive Technologies Inc
Priority to CA002158425A priority Critical patent/CA2158425C/fr
Publication of CA2158425A1 publication Critical patent/CA2158425A1/fr
Application granted granted Critical
Publication of CA2158425C publication Critical patent/CA2158425C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA002158425A 1995-09-15 1995-09-15 Diagnostic et traitement pour les dysfonctions erectiles Expired - Lifetime CA2158425C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002158425A CA2158425C (fr) 1995-09-15 1995-09-15 Diagnostic et traitement pour les dysfonctions erectiles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002158425A CA2158425C (fr) 1995-09-15 1995-09-15 Diagnostic et traitement pour les dysfonctions erectiles

Publications (2)

Publication Number Publication Date
CA2158425A1 CA2158425A1 (fr) 1997-03-16
CA2158425C true CA2158425C (fr) 2003-01-28

Family

ID=4156606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002158425A Expired - Lifetime CA2158425C (fr) 1995-09-15 1995-09-15 Diagnostic et traitement pour les dysfonctions erectiles

Country Status (1)

Country Link
CA (1) CA2158425C (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487073B2 (en) 2008-06-09 2013-07-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US10017539B2 (en) 2009-11-23 2018-07-10 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic hexapeptides

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487073B2 (en) 2008-06-09 2013-07-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US8729224B2 (en) 2008-06-09 2014-05-20 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of female sexual dysfunction
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US9580466B2 (en) 2009-11-23 2017-02-28 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US10017539B2 (en) 2009-11-23 2018-07-10 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic hexapeptides
US10106578B2 (en) 2009-11-23 2018-10-23 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides

Also Published As

Publication number Publication date
CA2158425A1 (fr) 1997-03-16

Similar Documents

Publication Publication Date Title
EP0696919B1 (fr) Diagnostic et traitement des dysfonctionnements erectiles
Ottesen et al. Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter.
TW487711B (en) Conjugates of lipophilic moieties and peptides
US5891849A (en) Methods and formulations for preventing progression of neuropathic pain
RU2098120C1 (ru) Фармацевтическая композиция для индуцирования эрекции у мужчин (варианты)
Gozes et al. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist
JP2682702B2 (ja) Ｖｉｐまたはその活性フラグメントと疎水性部分とのコンジュゲート及び男性のインポテンツのための局所投与用組成物
Itoh et al. Adrenocortical stimulation by a cholecystokinin preparation in the rat
Ferin et al. Endogenous opioid peptides and the control of the menstrual cycle
CA2218173A1 (fr) Analogues du facteur liberant l'hormone de croissance
Malven et al. Effects of naloxone and electroacupuncture treatment on plasma concentrations of LH in sheep
AU679241B2 (en) Anti-inflammatory composition and method with DES-TYR dynorphin and analogues
Gozes et al. A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model.
Olson et al. Neuropeptides and the blood-brain barrier in goldfish
CA2158425C (fr) Diagnostic et traitement pour les dysfonctions erectiles
Kumachev et al. Poisoning from the Kambô ritual
US4351829A (en) Use of polypeptides as analgesic drugs
EP0540969A2 (fr) Dérivés de VIP modifié et leurs compositions
US20030036514A1 (en) Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction
FI79716C (fi) Daeggdjur-pgrf.
Guillemin Hypothalamic hormones: releasing and inhibiting factors
JPH09504792A (ja) 慢性関節リウマチに関する治療
RU2242241C1 (ru) Тетрапептид, регулирующий уровень глюкозы при сахарном диабете, фармакологическое средство на его основе и способ его применения
Mooradian et al. Biweekly intracavernous administration of papaverine for erectile dysfunction.
Rossitch Jr et al. The deafferentation syndrome in the rat: effects of intraventricular neurotensin and cholecystokinin

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150915